Tachycardia-Induced Cardiomyopathy: Evaluation and Therapeutic Options

Authors

  • Anton Lishmanov MD, PhD,

    1. From the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO;
    Search for more papers by this author
  • Priya Chockalingam MBBS, MRCPCH,

    1. the Department of Cardiology and Pediatric Cardiology, Academic Medical Centre, Amsterdam, Netherlands;
    Search for more papers by this author
  • Annamalai Senthilkumar MD,

    1. From the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO;
    2. the Cardiology Section, Harry S. Truman VA Medical Center, Columbia, MO
    Search for more papers by this author
  • Anand Chockalingam MD

    1. From the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO;
    2. the Cardiology Section, Harry S. Truman VA Medical Center, Columbia, MO
    Search for more papers by this author

Anand Chockalingam, MD, Internal Medicine, Division of Cardiology, University of Missouri–Columbia, Five Hospital Drive, CE306, Columbia, MO 65212
E-mail: chockalingama@health.missouri.edu

Abstract

Tachycardia-induced cardiomyopathy is caused by sustained rapid ventricular rates and is one of the well-known forms of reversible myocardial dysfunction. The diagnosis is usually made retrospectively after marked improvement in systolic function is noted following control of the heart rate. Physicians should be aware that patients with seemingly idiopathic systolic dysfunction may have tachycardia-induced cardiomyopathy and that controlling the heart rate may result in improvement or even complete restoration of systolic function. Congest Heart Fail. 2010;16:122–126. © 2010 Wiley Periodicals, Inc.

Ancillary